Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAft Pharmaceuticals Ltd

Aft Pharmaceuticals Ltd

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
3.59 AUD 0.00(0%)
Last update at 2026-11-05T22:59:00Z
VOLUME
5
Market Cap
376.50M
P/E
29.92

Momentum Score

…

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a research and development collaboration with Hyloris Pharmaceuticals SA for the development of the Maxigesic IV product. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.59
Low
3.59
High
52 Week Price Range
2.69
Low
4.13
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

AFT Pharmaceuticals is a New Zealand specialty pharma group that develops, registers and markets branded prescription and over‑the‑counter medicines for domestic and export markets. Long‑term growth may be driven by in‑licensing, acquisitions and expanded regulatory approvals to support deeper international distribution. The company appears positioned to benefit from a diversified consumer healthcare portfolio and growing demand in key export markets.

Material risks include regulatory delays, competition from generics and branded rivals, execution risk in overseas expansion, concentration in a few core products or markets, and supply‑chain and currency exposure.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.59
Dividend Yield
0.71%
Revenue TTM
254.70M
Revenue Per Share
2.43
Gross Profit TTM
110.55M
Debt / Equity
0.49
ROE
13.66%
Net Debt
44.19M
ROCE
16.50%
Diluted EPS TTM
0.12

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax 22.03M 16.03M 22.02M 15.80M 18.68M
Minority interest 0.65M 0.56M - - -
Net income 14.84M 11.96M 15.61M 10.65M 19.85M
Selling general administrative 74.62M 12.23M 11.21M 11.12M 7.77M
Selling and marketing expenses - 51.09M 45.26M 38.28M 30.22M
Gross profit 111.36M 89.19M 86.89M 72.98M 61.77M
Reconciled depreciation 3.70M 2.67M 2.01M 1.72M 1.04M
Ebit 25.04M 18.86M 25.70M 19.67M 20.39M
Ebitda 28.76M 21.52M 27.72M 19.88M 20.67M
Depreciation and amortization 3.73M 2.67M 2.01M 0.21M 0.28M
Operating income 25.04M 11.70M 20.32M 19.67M 20.39M
Other operating expenses 231.52M 193.79M 173.72M 137.98M 109.20M
Interest expense 2.51M 2.82M 3.69M 2.87M 2.44M
Tax provision 7.79M 4.63M 6.41M 5.14M -1.16M
Interest income -0.09M 0.03M 0.07M 0.01M 0.00M
Net interest income -2.57M -2.80M -3.62M -2.86M -2.43M
Income tax expense 7.85M 4.63M 6.41M 5.14M 1.16M
Total revenue 256.56M 205.49M 194.03M 156.64M 130.31M
Total operating expenses 86.32M 77.49M 66.58M 54.32M 40.66M
Cost of revenue 145.20M 116.31M 107.14M 83.66M 68.54M
Total other income expense net -3.00M 4.33M 1.70M -3.87M -1.70M
Net income from continuing ops 14.08M 11.40M 15.61M 10.65M 19.85M
Net income applicable to common shares - - - 10.65M 19.85M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 218.59M - 165.26M 148.06M 121.76M
Intangible assets 64.77M - 53.46M 45.63M 38.09M
Other current assets - - 0.41M 7.84M 6.24M
Total liab 108.73M - 77.46M 74.80M 65.02M
Total stockholder equity 111.08M - 87.80M 73.27M 56.74M
Deferred long term liab - - - 29.46M 22.11M
Other current liab 24.42M - 11.93M 17.59M 16.98M
Common stock 78.81M - 78.24M 78.24M 77.61M
Capital stock 78.24M - - 78.24M 77.61M
Retained earnings 32.62M - 9.26M -5.20M -21.42M
Other assets - - - 33.93M 24.87M
Cash 10.31M - 12.04M 4.75M 7.94M
Total current liabilities 66.83M - 46.07M 39.77M 29.05M
Current deferred revenue - - - -3.03M -4.54M
Net debt 44.19M - 19.35M 33.30M 32.57M
Short term debt 12.60M - - 3.03M 4.54M
Short long term debt 11.58M - - 2.46M 4.00M
Short long term debt total 54.50M - 31.39M 38.05M 40.51M
Other stockholder equity - - - -2.94M -2.61M
Property plant equipment - - - 3.37M 3.36M
Total current assets 149.62M - 105.73M 94.60M 77.54M
Net tangible assets - - - 57.10M 40.76M
Net receivables 64.70M - 44.22M 39.62M 29.87M
Long term debt 39.00M - - 32.20M 33.20M
Inventory 74.61M - 49.06M 42.40M 33.50M
Accounts payable 29.81M - 34.14M 22.18M 12.07M
Accumulated other comprehensive income -0.34M - 0.30M 0.23M 0.55M
Non currrent assets other - - 2.25M -19.53M -19.35M
Non current assets total 68.97M - 59.53M 53.46M 44.22M
Capital lease obligations 3.53M - - 3.39M 3.31M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments - -6.95M -9.53M -9.18M -5.58M
Change to liabilities - - - 12.67M -2.66M
Total cashflows from investing activities -9.83M -6.95M -9.53M -9.18M -5.58M
Net borrowings 13.40M -1.52M -5.00M -4.59M -2.02M
Total cash from financing activities 11.09M -6.81M -10.63M -6.98M -2.28M
Net income 14.84M 11.96M 15.61M 10.65M 19.85M
Change in cash -1.91M -0.93M 8.75M -4.65M 4.73M
Begin period cash flow 12.22M 12.04M 3.29M 7.94M 3.21M
End period cash flow 10.31M 11.11M 12.04M 3.29M 7.94M
Total cash from operating activities -11.84M 13.18M 28.86M 11.63M 14.15M
Issuance of capital stock - - - 0.47M 0.29M
Depreciation 3.73M - 2.01M 0.85M 0.91M
Other cashflows from investing activities - -6.67M -9.41M - -
Dividends paid 1.90M -1.68M -1.15M - -
Change to inventory -25.78M 0.58M -6.66M -8.90M 0.15M
Change to account receivables -15.79M -4.34M 2.50M -10.72M -4.96M
Other cashflows from financing activities -1.13M -3.62M -4.48M -2.86M 2.81M
Change to netincome - - - 6.20M 0.73M
Capital expenditures 0.12M 6.95M 9.53M 0.20M 0.33M
Change in working capital -34.42M -3.76M -4.16M -19.61M -4.81M
Stock based compensation - - 0.14M - 0.01M
Other non cash items 4.03M 16.94M 15.26M 19.74M -6.61M
Free cash flow -11.95M 6.22M 19.33M 11.43M 13.82M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AFP
Aft Pharmaceuticals Ltd		 -
-%		 3.59 29.92 18.18 1.48 4.37 2.05 18.56
VLS
Vita Life Sciences Ltd		 -
-%		 2.70 13.50 42.73 1.52 2.62 1.19 7.17
LGP
Little Green Pharma Ltd		 -
-%		 0.06 - 10.00 0.64 0.60 1.25 19.47
MVP
Medical Developments International Ltd		 -
-%		 0.40 40.00 166.67 1.06 0.79 0.57 7.45
SNT
Syntara Ltd		 -
-%		 0.02 - 20.45 5.10 2.18 6.32 -2.16

Profile*

Aft Pharmaceuticals Ltd

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a research and development collaboration with Hyloris Pharmaceuticals SA for the development of the Maxigesic IV product. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.

129 Hurstmere Road, Auckland, New Zealand, 0622

64 8 0042 3823

https://www.aftpharm.com

126

Name Title Year Born
Dr. Hartley Atkinson Ph.D. Co-Founder, CEO, MD & Exec. Director NA
Ms. Marree Atkinson Co-Founder, Chief of Staff & Exec. Director NA
Mr. Malcolm Tubby B.A., BA(Hon's), ICAEW, ICANZ CFO & Company Sec. NA
Mr. Murray Keith Group Marketing Mang. NA
Ms. Ioana Stanescu Head of Drug Devel. NA
Mr. Calvin Mackenzie Gen. Mang. of AFT Australia NA
Mr. Scott Crawford Gen. Mang. of Promoted Products Australasia & South East Asia NA
Ms. Louise Clayton Director of International Bus. NA
Dr. Hartley Atkinson Ph.D. Co-Founder, CEO, MD & Executive Director NA
Ms. Marree Atkinson Co-Founder, Chief of Staff & Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…